Happy to share our manuscript titled 'Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy' published in JAMA Oncology! @jama.com jamanetwork.com/journals/jam...

Can patterns of progression on IO, inform future decisions? -1377pts from 5 ph 3 trials used to create 3 PD risk levels - low (⬆️existing lesions), intermediate (new lesions), high (both) - risk score assoc w post-PD OS across tumors Prognostic, so far #LCSM jamanetwork.com/journals/jam...

Great review! NECTIN4 is an exciting target. More to come ! #cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker

Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24

Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12… ➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases! @ptarantinomd.bsky.social @markuseckstein3.bsky.social